Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.35 |
| ▸ | PDE2A | O00408 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173610 | 0.87 | IGF1R (0.37) | IGF1RSMN1; SMN2 | |
| SCHEMBL6174287 | 0.87 | IGF1R (0.38) | IGF1RSMN1; SMN2 | |
| SCHEMBL6175589 | 0.85 | IGF1R (0.38) | IGF1RPDE2ASMN1; SMN2 | |
| SCHEMBL6173494 | 0.84 | IGF1R (0.33) | IGF1RPDE2A | |
| SCHEMBL6174393 | 0.82 | SMN1; SMN2 (0.43) | IGF1RSMN1; SMN2 | |
| SCHEMBL6176997 | 0.82 | KDM4E (0.42) | PDE2ASMN1; SMN2AR | |
| SCHEMBL6173968 | 0.81 | IGF1R (0.35) | IGF1RPDE2A | |
| SCHEMBL6173598 | 0.80 | IGF1R (0.39) | IGF1RPDE2A | |
| SCHEMBL6174902 | 0.80 | SMN1; SMN2 (0.39) | IGF1RSMN1; SMN2 | |
| SCHEMBL6172293 | 0.80 | IGF1R (0.40) | IGF1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |